Kosan Biosciences Incorporated
Kosan Biosciences Incorporated, often referred to as Kosan, is a pioneering biotechnology company headquartered in the United States. Founded in the early 2000s, Kosan has established itself as a leader in the development of innovative therapeutics, particularly in the fields of cancer and infectious diseases. The company focuses on harnessing the power of its proprietary drug discovery platform, which utilises advanced molecular technologies to create unique small-molecule therapeutics. Kosan's commitment to scientific excellence has led to significant milestones, including successful clinical trials and partnerships with major pharmaceutical firms. With a strong market position, Kosan continues to make strides in the biotechnology industry, aiming to deliver transformative treatments that address unmet medical needs. Its dedication to research and development sets it apart, making Kosan a notable player in the competitive landscape of biopharmaceuticals.
DitchCarbon Score
How does Kosan Biosciences Incorporated's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kosan Biosciences Incorporated's score of 71 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kosan Biosciences Incorporated, headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Bristol-Myers Squibb Company, which may influence its climate commitments and reporting practices. As part of its corporate family, Kosan Biosciences inherits climate initiatives and targets from Bristol-Myers Squibb. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across various scopes. However, specific reduction targets or achievements for Kosan Biosciences are not detailed in the available data. Kosan's climate strategy may align with broader industry standards, focusing on reducing emissions through sustainable practices and innovation. As the company continues to develop its environmental commitments, it is essential to monitor any future disclosures that may provide clarity on its carbon footprint and reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kosan Biosciences Incorporated is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
